Skip to content

Effect of combined dexamethasone-ondansetrone versus dexamethasone and ondansetrone alone for the prevention of nausea and vomiting after outpatient gynecological diagnostic laparoscopy

Effect of dexamethasone-ondansetrone for the prevention of nausea and vomiting after laparoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014012511700N3
Enrollment
105
Registered
2014-02-05
Start date
2013-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and Vomiting. Other complications of spinal and epidural anaesthesia during labour and delivery

Interventions

Intervention 1: Group 1, will recieve 8 mg IV Dexamethazone before induction of anesthesia. Intervention 2: Group2 will recieve 4 mg IV ondansetron before induction of anesthesia. Intervention 3: Grou
Treatment - Drugs
Group 1, will recieve 8 mg IV Dexamethazone before induction of anesthesia
Group2 will recieve 4 mg IV ondansetron before induction of anesthesia
Group 3 will recieve 8 mg Dexamethazone and 4 mg Ondansetron IV before induction of anesthesia

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: women with 20-50 years old; women with ASA physical status I and II; patients who have given informed concent Exclusio criteria: patients with ASA physical status III or higher;cardiovascular disease; respiratory disease; gastrointestinal disease; hypertension; diabet; patients who had antiemetic therapy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Nausea and Vomiting. Timepoint: In recovery room and until discharge of Hospital. Method of measurement: The intencity of nausea and vomiting with Belville score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farnaz Moslemi

Tabriz University of Medical Sciences

moslemi_fa@yahoo.com+98 41 1553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026